Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized...
Q2 2026
Aug 6, 2026
Q1 2026
May 5, 2026
FY 2025
Feb 26, 2026
Q4 2025
Q3 2025
Nov 5, 2025
